HUP9900886A2 - Biszfoszfonátok alkalmazása immunszupresszív terápiával kapcsolatos csontvesztés megelőzésére és kezelésére alkalmas gyógyászati készítmények előállítására - Google Patents

Biszfoszfonátok alkalmazása immunszupresszív terápiával kapcsolatos csontvesztés megelőzésére és kezelésére alkalmas gyógyászati készítmények előállítására

Info

Publication number
HUP9900886A2
HUP9900886A2 HU9900886A HUP9900886A HUP9900886A2 HU P9900886 A2 HUP9900886 A2 HU P9900886A2 HU 9900886 A HU9900886 A HU 9900886A HU P9900886 A HUP9900886 A HU P9900886A HU P9900886 A2 HUP9900886 A2 HU P9900886A2
Authority
HU
Hungary
Prior art keywords
bisphosphonates
immunosuppressive therapy
bone loss
preparation
loss associated
Prior art date
Application number
HU9900886A
Other languages
English (en)
Inventor
Anastasia G. Daifotis
Ashley J. Yates
Original Assignee
Merck & Co.,Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co.,Inc. filed Critical Merck & Co.,Inc.
Publication of HUP9900886A2 publication Critical patent/HUP9900886A2/hu
Publication of HUP9900886A3 publication Critical patent/HUP9900886A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A találmány értelmében a biszfoszfonátok, különösen az alendronátimmunszuppresszív terápiával kapcsolatos csontvesztés kezelésére vagymegelőzésére alkalmas gyógyászati készítmények előállításáraalkalmazható, attól függetlenül, hogy az immunszuppresszív terápiátszervátültetéssel kapcsolatosan alkalmazzák-e vagy sem. Ó
HU9900886A 1995-06-06 1996-06-03 Use of bisphosphonates preventing bone loss associated with immunosuppressive therapy for the preparation of pharmaceutical compositions HUP9900886A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/471,466 US5616571A (en) 1995-06-06 1995-06-06 Bisphosphonates prevent bone loss associated with immunosuppressive therapy
PCT/US1996/008398 WO1996039151A1 (en) 1995-06-06 1996-06-03 Bisphosphonates prevent bone loss associated with immunosuppressive therapy

Publications (2)

Publication Number Publication Date
HUP9900886A2 true HUP9900886A2 (hu) 2001-04-28
HUP9900886A3 HUP9900886A3 (en) 2002-04-29

Family

ID=23871741

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9900886A HUP9900886A3 (en) 1995-06-06 1996-06-03 Use of bisphosphonates preventing bone loss associated with immunosuppressive therapy for the preparation of pharmaceutical compositions

Country Status (14)

Country Link
US (1) US5616571A (hu)
EP (1) EP0831844A4 (hu)
JP (1) JPH11507044A (hu)
KR (1) KR19990022380A (hu)
CA (1) CA2223400A1 (hu)
CZ (1) CZ288906B6 (hu)
EA (1) EA000964B1 (hu)
HU (1) HUP9900886A3 (hu)
IL (1) IL122149A (hu)
NO (1) NO975692L (hu)
NZ (1) NZ310000A (hu)
PL (1) PL323797A1 (hu)
SK (1) SK163797A3 (hu)
WO (1) WO1996039151A1 (hu)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993009785A1 (en) * 1991-11-22 1993-05-27 Procter & Gamble Pharmaceuticals, Inc. Risedronate delayed-release compositions
JPH10504839A (ja) * 1995-02-17 1998-05-12 メルク エンド カンパニー インコーポレーテッド 非脊椎骨折のリスクを減少させる方法
PL332496A1 (en) * 1996-10-04 1999-09-13 Merck & Co Inc Liquid alendronate preparations
US20010031244A1 (en) * 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
AU741818C (en) * 1997-07-22 2003-01-09 Merck Sharp & Dohme Corp. Method for inhibiting bone resorption
US6432932B1 (en) 1997-07-22 2002-08-13 Merck & Co., Inc. Method for inhibiting bone resorption
US5994329A (en) 1997-07-22 1999-11-30 Merck & Co., Inc. Method for inhibiting bone resorption
US6087350A (en) * 1997-08-29 2000-07-11 University Of Pittsburgh Of The Commonwealth System Of Higher Education Use of pretreatment chemicals to enhance efficacy of cytotoxic agents
JP2002527400A (ja) * 1998-10-15 2002-08-27 メルク エンド カムパニー インコーポレーテッド 骨形成刺激方法
US6414006B1 (en) 1998-10-15 2002-07-02 Merck Frosst Canada & Co. Methods for inhibiting bone resorption
US6331533B1 (en) 1998-11-16 2001-12-18 Merck & Co., Inc. Method for inhibiting dental resorptive lesions
ATE301129T1 (de) 1999-05-04 2005-08-15 Strakan Int Ltd Androgen glykoside und die androgenische aktivität davon
AUPQ232599A0 (en) * 1999-08-19 1999-09-09 Royal Alexandra Hospital For Children, The Drug for treating fractures
US6677320B2 (en) * 2000-01-20 2004-01-13 Hoffmann-La Roches Inc. Parenteral bisphosphonate composition with improved local tolerance
DK1276482T3 (da) * 2000-03-02 2008-05-26 Univ Pittsburgh Kombinationskemoterapi
AU2002254082B2 (en) * 2001-03-01 2007-05-24 Emisphere Technologies, Inc. Compositions for delivering bisphosphonates
WO2003086415A1 (en) * 2002-04-05 2003-10-23 Merck & Co., Inc. Method for inhibiting bone resorption with an alendronate and vitamin d formulation
US20040138180A1 (en) * 2002-10-03 2004-07-15 Barr Laboratories, Inc. Bisphosphonate composition and process for the preparation thereof
US20040097468A1 (en) * 2002-11-20 2004-05-20 Wimalawansa Sunil J. Method of treating osteoporosis and other bone disorders with upfront loading of bisphosphonates, and kits for such treatment
US20050181043A1 (en) * 2004-02-12 2005-08-18 Indranil Nandi Alendronate salt tablet compositions
US20050261250A1 (en) * 2004-05-19 2005-11-24 Merck & Co., Inc., Compositions and methods for inhibiting bone resorption
US20060134190A1 (en) * 2004-12-16 2006-06-22 Banner Pharmacaps Inc. Formulations of bisphosphonate drugs with improved bioavailability
KR20070121759A (ko) * 2005-03-17 2007-12-27 엘란 파마 인터내셔널 리미티드 나노입자형 비스포스포네이트 조성물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8530603D0 (en) * 1985-12-12 1986-01-22 Leo Pharm Prod Ltd Chemical compounds
SK74594A3 (en) * 1991-12-17 1995-01-12 Procter & Gamble Pharma Treatment for treating of osteoporosis
ATE161423T1 (de) * 1992-06-30 1998-01-15 Procter & Gamble Pharma Verwendung von phosphinate zur behandlung der osteoporose
US5536716A (en) * 1992-12-11 1996-07-16 Merck & Co., Inc. Spiro piperidines and homologs which promote release of growth hormone
WO1994014455A1 (en) * 1992-12-23 1994-07-07 Merck & Co., Inc. Bisphosphonate/estrogen therapy for treating and preventing bone loss
US5366965A (en) * 1993-01-29 1994-11-22 Boehringer Mannheim Gmbh Regimen for treatment or prophylaxis of osteoporosis
US5462932A (en) * 1994-05-17 1995-10-31 Merck & Co., Inc. Oral liquid alendronate formulations
NZ272608A (en) * 1994-07-22 2000-05-26 Lilly Co Eli Inhibiting bone loss by administering a bisphosphonate and a second compound selected from various compounds, including 2-phenyl-3-aroylbenzothienes; bisphosphonate combination salts
US5780455A (en) * 1994-08-24 1998-07-14 Merck & Co., Inc. Intravenous alendronate formulations
WO1996007418A1 (en) * 1994-09-09 1996-03-14 The Procter & Gamble Company Phosphonates and parathyroid hormone for osteoporosis

Also Published As

Publication number Publication date
AU696097B2 (en) 1998-09-03
IL122149A0 (en) 1998-04-05
PL323797A1 (en) 1998-04-27
CA2223400A1 (en) 1996-12-12
CZ288906B6 (cs) 2001-09-12
NO975692D0 (no) 1997-12-05
US5616571A (en) 1997-04-01
JPH11507044A (ja) 1999-06-22
KR19990022380A (ko) 1999-03-25
EA000964B1 (ru) 2000-08-28
WO1996039151A1 (en) 1996-12-12
CZ389897A3 (cs) 1998-07-15
EP0831844A4 (en) 1998-12-30
EP0831844A1 (en) 1998-04-01
EA199800011A1 (ru) 1998-06-25
SK163797A3 (en) 1998-07-08
NO975692L (no) 1997-12-05
IL122149A (en) 2001-03-19
HUP9900886A3 (en) 2002-04-29
AU6030996A (en) 1996-12-24
NZ310000A (en) 2000-07-28

Similar Documents

Publication Publication Date Title
HUP9900886A2 (hu) Biszfoszfonátok alkalmazása immunszupresszív terápiával kapcsolatos csontvesztés megelőzésére és kezelésére alkalmas gyógyászati készítmények előállítására
CA2257976A1 (en) Compositions and methods for coating medical devices
MXPA02007932A (es) Analogos de nucleosidos con base biciclica modificada con carboxamidina.
UA39158C2 (uk) Похідні n4-оксикарбоніл-5'-дезокси-5-фторцитидину та фармацевтичний препарат на їх основі
DE69713151D1 (de) Cyclosporinderivat, dessen herstellung und pharmazeutische zusammensetzung
FI880464A (fi) Bekaempningsmedel mot tandplaque och -karies.
ATE242633T1 (de) Dialkylfumarate zur behandlung von autoimmunerkrankungen
DE69427344D1 (de) Verabreichung von riluzol zur behandlung von neuro-aids
BR9711805A (pt) Compostos e métodos para providenciar preparações farmacologicamente ativas e uso dos mesmos
BR9713400A (pt) Processos e compostos para inibir liberação de peptìdeo beta-amilóide e/ou sua sìntese.
HUT60630A (en) Process or producing peroral pharmaceutical compositions suitable for treating internal diseases of inflammatory nature
AU5861799A (en) Use of acetylcholinesterase inhibitors for the preparation of pharmaceutical compositions for the treatment of functional and/or organic pain syndromes
ZA98214B (en) Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1.
ZA943744B (en) Therapeutic substituted guanidines
DE69033970D1 (de) Huperzin a analoge verbindungen
CA2264063A1 (en) Cryptophycin compounds
MXPA94009086A (es) Guanidinas sustituidas terapeuticas.
NO983177L (no) Anvendelse av 1-enantiomeren av centkroman til fremstilling av et farmasaytisk preparat for behandling eller profylakse av brystkreft
HUP0202729A2 (hu) Ösztramusztin-foszfátot és aminosavakat tartalmazó, parenteralis felhasználásra szolgáló készítmények
IL134263A0 (en) Use of phanquinone for the treatment of alzheimer's disease
EP0869786A4 (en) PHARMACEUTICAL COMPOUNDS
BG106151A (en) Pharmaceutical complex
HUP9904578A2 (hu) Xanomelin alkalmazása bipoláris depresszió kezelésére szolgáló gyógyszerkészítmények előállítására
BG103859A (en) The use of 1-ar(alk)yl-imidazolin-2-on for the treatment of fear and stress conditions
UA41326C2 (uk) Фармацевтична композиція для профілактики або лікування вірусних захворювань, засіб для профілактики або лікування вірусних захворювань